Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Quarterly Sales of $93.85 Million

Equities analysts forecast that Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will report $93.85 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $89.50 million to $99.90 million. Ironwood Pharmaceuticals posted sales of $94.21 million during the same quarter last year, which suggests a negative year over year growth rate of 0.4%. The firm is expected to announce its next quarterly earnings results on Thursday, February 21st.

On average, analysts expect that Ironwood Pharmaceuticals will report full year sales of $315.28 million for the current year, with estimates ranging from $305.40 million to $342.30 million. For the next financial year, analysts forecast that the firm will post sales of $393.59 million, with estimates ranging from $341.31 million to $474.70 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.24). The firm had revenue of $68.69 million for the quarter, compared to analysts’ expectations of $93.48 million. During the same quarter last year, the company earned ($0.18) EPS. The business’s revenue was down 20.9% on a year-over-year basis.

Several research analysts have recently issued reports on IRWD shares. Wells Fargo & Co set a $19.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 31st. Wedbush restated a “neutral” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, November 7th. Morgan Stanley set a $11.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “sell” rating in a report on Wednesday, November 7th. BTIG Research set a $17.00 target price on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Finally, ValuEngine cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 31st. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $16.45.

Shares of Ironwood Pharmaceuticals stock opened at $13.62 on Friday. Ironwood Pharmaceuticals has a 52-week low of $11.02 and a 52-week high of $21.20. The company has a market capitalization of $2.01 billion, a PE ratio of -14.65 and a beta of 1.33.

In related news, Director Julie Mchugh sold 1,500 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $19.10, for a total value of $28,650.00. Following the completion of the sale, the director now owns 91,131 shares of the company’s stock, valued at $1,740,602.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark G. Currie sold 116,651 shares of the firm’s stock in a transaction on Friday, October 5th. The stock was sold at an average price of $17.53, for a total value of $2,044,892.03. Following the completion of the sale, the insider now directly owns 70,680 shares of the company’s stock, valued at approximately $1,239,020.40. The disclosure for this sale can be found here. Insiders sold 119,509 shares of company stock valued at $2,089,580 in the last ninety days. 7.63% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in IRWD. Pacer Advisors Inc. purchased a new stake in Ironwood Pharmaceuticals in the third quarter worth $177,000. Meeder Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals during the second quarter valued at $186,000. Campbell & CO Investment Adviser LLC purchased a new position in Ironwood Pharmaceuticals during the third quarter valued at $249,000. PNC Financial Services Group Inc. lifted its position in Ironwood Pharmaceuticals by 17,621.9% during the second quarter. PNC Financial Services Group Inc. now owns 17,013 shares of the biotechnology company’s stock valued at $325,000 after buying an additional 16,917 shares during the period. Finally, Aperio Group LLC lifted its position in Ironwood Pharmaceuticals by 34.2% during the second quarter. Aperio Group LLC now owns 21,185 shares of the biotechnology company’s stock valued at $405,000 after buying an additional 5,404 shares during the period. 95.84% of the stock is owned by institutional investors.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names.

See Also: Intrinsic Value and Stock Selection

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply